Materials And Products Tenders

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Ranibizumab, as a Vial (S01la04) as Part of an Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Interferon Beta-1B (L03ab08) as Part of a So-Called Open House Model.

Polbln 128_23 Framework Contract Transcription Audiovisual Interrogations

Drugs with the Active Ingredient Diclofenac (Atc Code: D11ax18 - Topical Dosage Forms Only)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Metoclopramide (A03fa01) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredients Tamsulosin and Dutasteride (G04ca52) as Part of a So-Called Open House Model.

Open House Discount Drug Contracts Fulvestrant, Atc L02ba03

Open House Discount Drug Contracts Tamsulosin and Dutasteride, Atc G04ca52

Medicines with the Active Substance Combination Metoprolol and Hydrochlorothiazide (Atc: C07bb22)

Open Framework Agreement on Drug Discounts in Accordance with § 130A Paragraph 8 Sgb V with the Option to Join at any Time, So-Called Approval Model 2023-04